contact

PD Dr. Arnoud Templeton

titel PD Dr. med.

first name Arnoud

last name Templeton

street Rorschacherstrasse 95

city 9007 St. Gallen

country Switzerland

phone number +41 (0)71 494 10 67

fax +41 (0)71 494 63 25

e-mail arnoud.templeton@kssg.ch

homepage www.oncocenter.ch

2

research profile

academic status Oberarzt/Oberärztin

department I

faculty Onkologie/Hämatologie

position Oberarzt Medinische Onkologie

Swiss Board certification medical oncology 2010ESMO examination medical oncology 2009Swiss Board certification internal medicine 2008

fields of research 1. Castrastion Resistant Prostate Cancer (CRPC)2. Survivorship breast cancer

former positions 07/08 – 06/09 Breast center St. Gallen (Prof. B.Thürlimann)01/07 – 06/08 Medical Oncology St. Gallen (Prof.Th. Cerny)01/06 – 12/06 Infectiologiy St. Gallen (Prof. P.Vernazza)04/05 – 12/05 Internal Medicine St. Gallen (Prof.P. Greminger)02/03 – 02/05 Internal Medicine Zofingen (Dr. H.Vonesch)

affiliations FMH (since 2003)VSAO (since 2003, Co-President Section St. Gallensince 2007)ESMO (since 2006)SAKK Project group urogenital tumors (since 2007)ASCO (since 2008)Flims Alumni Club (member of steering committee,since 2008)

3

publications

title

journalpaper/review

Vera-Badillo F E, Chang M C, Kuruzar G, Ocaña A, Templeton A, SerugaB, Goldstein R, Bedard P L, Tannock I F, Amir E. Association betweenandrogen receptor expression, Ki-67 and the 21-gene recurrence score innon-metastatic, lymph node-negative, estrogen receptor-positive andHER2-negative breast cancer. J Clin Pathol 2015;.

Schlaeppi M, Templeton A. Möglichkeiten und Grenzen derKomplementärmedizin in der Onkologie. Onkologische Pharmazie 2015;1:46-50.

AlHashem H Y, Al-Mubarak M, Vera-Badillo F E, Templeton A, Ocana A,Šeruga B, Amir E. Impact of Geographic Region on Benefit of ApprovedAnticancer Drugs Evaluated in International Phase III Clinical Trials. ClinOncol (R Coll Radiol) 2015;.

Sonpavde G, Pond G R, Templeton A, Fandi A, Tombal B, Rosenthal M,Armstrong A J, Petrylak D P. Association Between RECIST Changes andSurvival in Patients with Metastatic Castration-resistant Prostate CancerReceiving Docetaxel. Eur Urol 2015;.

Templeton A, Ace O, Amir E, Vera-Badillo F, Ocaña A, Pond G R, Tannock IF. Influence of censoring on conclusions of trials for women withmetastatic breast cancer. Eur J Cancer 2015;.

Ocaña A, Ethier J L, Diez-Gonzalez L, Corrales-Sánchez V, Srikanthan A,Gascón-Escribano M J, Templeton A, Vera-Badillo F, Seruga B, Niraula S,Pandiella A, Amir E. Influence of companion diagnostics on efficacy andsafety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015;.

Ocaña A, Diez-Gonzalez L, Garcia-Olmo D C, Templeton A, Vera-Badillo F,Gascon-Escribano M J, Serrano-Heras G, Corrales-Sánchez V, Seruga B,Andrés-Pretel F, Pandiella A, Amir E. Circulating DNA and survival in solidtumors. Cancer Epidemiol Biomarkers Prev 2015;.

4

publications

title

journalpaper/review

Templeton A, Šeruga B. Primum non nocere. Ann Oncol 2015;26:2197-8.

Vera-Badillo F E, Napoleone M, Ocaña A, Templeton A, Seruga B, Al-Mubarak M, AlHashem H, Tannock I F, Amir E. Effect of multifocality andmulticentricity on outcome in early stage breast cancer: a systematicreview and meta-analysis. Breast Cancer Res Treat 2014; 146:235-44.

Vera-Badillo F E, Templeton A, Duran I, Ocaña A, de Gouveia P, Aneja P,Knox J J, Tannock I F, Escudier B, Amir E. Systemic Therapy for Non-clearCell Renal Cell Carcinomas: A Systematic Review and Meta-analysis. EurUrol 2014;.

Sonpavde G, Pond G R, Armstrong A J, Clarke S J, Vardy J L, TempletonA, Wang S L, Paolini J, Chen I, Chow-Maneval E, Lechuga M, Smith M R,Michaelson M D. Prognostic impact of the neutrophil-to-lymphocyte ratioin men with metastatic castration-resistant prostate cancer. ClinGenitourin Cancer 2014; 12:317-24.

Templeton A, Pezaro C, Omlin A, McNamara M G, Leibowitz-Amit R, Vera-Badillo F E, Attard G, de Bono J S, Tannock I F, Amir E. Simple prognosticscore for metastatic castration-resistant prostate cancer withincorporation of neutrophil-to-lymphocyte ratio. Cancer 2014;120:3346-52.

Templeton A, Ace O, McNamara M G, Al-Mubarak M, Vera-Badillo F E,Hermanns T, Seruga B, Ocaña A, Tannock I F, Amir E. Prognostic role ofplatelet to lymphocyte ratio in solid tumors: a systematic review andmeta-analysis. Cancer Epidemiol Biomarkers Prev 2014; 23:1204-12.

5

publications

title

journalpaper/review

Hermanns T, Bhindi B, Wei Y, Yu J, Noon A P, Richard P O, Bhatt J R,Almatar A, Jewett M A S, Fleshner N E, Zlotta A R, Templeton A, KulkarniG S. Pre-treatment neutrophil-to-lymphocyte ratio as predictor ofadverse outcomes in patients undergoing radical cystectomy forurothelial carcinoma of the bladder. Br J Cancer 2014; 111:444-51.

Schlaeppi M, Templeton A. Komplementärmedizin in der Onkologie: Wasder Grundversorger wissen sollte. Swiss Medical Forum 2014;14:689-693.

Ocana A, Vera-Badillo F, Al-Mubarak M, Templeton A, Corrales-Sanchez V,Diez-Gonzalez L, Cuenca-Lopez M D, Seruga B, Pandiella A, Amir E.Activation of the PI3K/mTOR/AKT Pathway and Survival in Solid Tumors:Systematic Review and Meta-Analysis. PLoS ONE 2014; 9:e95219.

Al-Mubarak M, Tibau A, Templeton A, Cescon D W, Ocaña A, Seruga B,Amir E. Extended adjuvant tamoxifen for early breast cancer: a meta-analysis. PLoS ONE 2014; 9:e88238.

Templeton A, Diez-Gonzalez L, Ace O, Vera-Badillo F, Seruga B, Jordán J,Amir E, Pandiella A, Ocaña A. Prognostic relevance of receptor tyrosinekinase expression in breast cancer: a meta-analysis. Cancer Treat Rev2014; 40:1048-55.

Leibowitz-Amit R, Alimohamed N, Vera-Badillo F E, Seah J A, TempletonA, Knox J J, Tannock I F, Sridhar S S, Joshua A M. Retreatment of menwith metastatic castrate-resistant prostate cancer with abiraterone.Prostate 2014; 74:1462-4.

6

publications

title

journalpaper/review

Leibowitz-Amit R, Seah J A, Atenafu E G, Templeton A, Vera-Badillo F E,Alimohamed N, Knox J J, Tannock I F, Sridhar S S, Joshua A M.Abiraterone acetate in metastatic castration-resistant prostate cancer: aretrospective review of the Princess Margaret experience of (I) low doseabiraterone and (II) prior ketoconazole. Eur J Cancer 2014;50:2399-407.

Vera-Badillo F E, Ocaña A, Templeton A, Tibau A, Amir E, Tannock I F.Raising concern about the American Society of Clinical Oncology conflictof interest policy amendment. J Clin Oncol 2014; 32:3197.

McNamara M G, Templeton A, Maganti M, Walter T, Horgan A M,McKeever L, Min T, Amir E, Knox J J. Neutrophil/lymphocyte ratio as aprognostic factor in biliary tract cancer. Eur J Cancer 2014; 50:1581-9.

Templeton A, McNamara M G, Seruga B, Vera-Badillo F E, Aneja P, OcañaA, Leibowitz-Amit R, Sonpavde G, Knox J J, Tran B, Tannock I F, Amir E.Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: asystematic review and meta-analysis. J Natl Cancer Inst 2014; 106:dju124.

Rocha P, Morgan C J, Templeton A, Pond G R, Naik G, Sonpavde G.Prognostic impact of C-reactive protein in metastatic prostate cancer: asystematic review and meta-analysis. Oncol Res Treat 2014; 37:772-6.

van Soest R J, Templeton A, Vera-Badillo F E, Mercier F, Sonpavde G,Amir E, Tombal B, Rosenthal M, Eisenberger M A, Tannock I F, de Wit R.Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men withmetastatic castration-resistant prostate cancer receiving first-linechemotherapy: data from two randomized phase III trials†. Ann Oncol2014;.

7

publications

title

journalpaper/review

Kroeger N, Pantuck A J, Wells J C, Lawrence N, Broom R, Kim J J,Srinivas S, Yim J, Bjarnason G A, Templeton A, Knox J, Bernstein E,Smoragiewicz M, Lee J, Rini B I, Vaishampayan U N, Wood L A,Beuselinck B, Donskov F, Choueiri T K, Heng D Y. Characterizing theImpact of Lymph Node Metastases on the Survival Outcome forMetastatic Renal Cell Carcinoma Patients Treated with TargetedTherapies. Eur Urol 2014;.

Leibowitz-Amit R, Templeton A, Alibhai S M, Knox J J, Sridhar S S,Tannock I F, Joshua A M. Efficacy and toxicity of abiraterone anddocetaxel in octogenarians with metastatic castration-resistant prostatecancer. J Geriatr Oncol 2014; 6:23-8.

Lorente D, Mateo J, Templeton A, Zafeiriou Z, Bianchini D, Ferraldeschi R,Bahl A, Shen L, Su Z, Sartor O, de Bono J S. Baseline neutrophil-lymphocyte ratio (NLR) is associated with survival and response totreatment with second-line chemotherapy for advanced prostate cancerindependent of baseline steroid use. Ann Oncol 2014;.

Leibowitz-Amit R, Templeton A, Omlin A, Pezaro C, Atenafu E G, KeizmanD, Vera-Badillo F, Seah J A, Attard G, Knox J J, Sridhar S S, Tannock I F,de Bono J S, Joshua A M. Clinical variables associated with PSA responseto abiraterone acetate in patients with metastatic castration-resistantprostate cancer. Ann Oncol 2014; 25:657-62.

Shao T, Wang L, Templeton A, Jang R, Vera-Badillo F W, McNamara M G,Margolis M, Kim T K, Sinaei M, Shoushtari H, Tannock I F. Use and misuseof waterfall plots. J Natl Cancer Inst 2014; 106:.

8

publications

title

journalpaper/review

Templeton A, Ribi K, Surber C, Sun H, Hsu Schmitz S F, Beyeler M,Dietrich D, Borner M, Winkler A, Müller A, von Rohr L, Winterhalder R C,Rochlitz C, von Moos R, Zaman K, Thürlimann B, Ruhstaller T, SwissGroup for Clinical Cancer Research (SAKK) Coordinating Center .Prevention of palmar-plantar erythrodysesthesia with an antiperspirant inbreast cancer patients treated with pegylated liposomal doxorubicin(SAKK 92/08). Breast 2014; 23:244-9.

McNamara M G, Lwin Z, Jiang H, Templeton A, Zadeh G, Bernstein M,Chung C, Millar B A, Laperriere N, Mason W P. Factors impacting survivalfollowing second surgery in patients with glioblastoma in thetemozolomide treatment era, incorporating neutrophil/lymphocyte ratioand time to first progression. J Neurooncol 2014; 117:147-52.

Rothermundt C, Hayoz S, Templeton A, Winterhalder R, Strebel R T,Bärtschi D, Pollak M, Lui L, Endt K, Schiess R, Rüschoff J H, Cathomas R,Gillessen Sommer S. Metformin in chemotherapy-naive castration-resistant prostate cancer: a multicenter phase 2 trial (SAKK 08/09). EurUrol 2014; 66:468-74.

Tibau A, Bedard P L, Srikanthan A, Ethier J L, Vera-Badillo F E, TempletonA, Ocaña A, Seruga B, Barnadas A, Amir E. Author financial conflicts ofinterest, industry funding, and clinical practice guidelines for anticancerdrugs. J Clin Oncol 2014; 33:100-6.

Vera-Badillo F E, Templeton A, de Gouveia P, Diaz-Padilla I, Bedard P L,Al-Mubarak M, Seruga B, Tannock I F, Ocaña A, Amir E. Androgenreceptor expression and outcomes in early breast cancer: a systematicreview and meta-analysis. J Natl Cancer Inst 2013; 106:djt319.

9

publications

title

journalpaper/review

Templeton A, Dutoit V, Cathomas R, Rothermundt C, Bärtschi D, Dröge C,Gautschi O, Borner M, Fechter E, Stenner F, Winterhalder R, Müller B,Schiess R, Wild P J, Rüschoff J H, Thalmann G, Dietrich P Y, Aebersold R,Klingbiel D, Gillessen Sommer S, Swiss Group for Clinical CancerResearch (SAKK) . Phase 2 trial of single-agent everolimus inchemotherapy-naive patients with castration-resistant prostate cancer(SAKK 08/08). Eur Urol 2013; 64:150-8.

Templeton A, Vera-Badillo F E, Wang L, Attalla M, De Gouveia P,Leibowitz-Amit R, Knox J J, Moore M, Sridhar S S, Joshua A M, Pond G R,Amir E, Tannock I F. Translating clinical trials to clinical practice:outcomes of men with metastatic castration resistant prostate cancertreated with docetaxel and prednisone in and out of clinical trials. AnnOncol 2013; 24:2972-7.

Vera-Badillo F E, Al-Mubarak M, Templeton A, Amir E. Benefit and harmsof new anti-cancer drugs. Curr Oncol Rep 2013; 15:270-5.

Hochstrasser A, Benz G, Joerger M, Templeton A, Brutsche M, Früh M.Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?.Chemotherapy 2012; 58:84-88.

Templeton A, Schlaeppi M. Anthroposophische Konzeptenaturwissenschaftlich beleuchtet. Schweizerische Ärztezeitung 2011;92:1558-1559.

Kälin M, Cima I, Schiess R, Fankhauser N, Powles T, Wild P, Templeton A,Cerny T, Aebersold R, Krek W, Gillessen Sommer S. Novel prognosticmarkers in the serum of patients with castration-resistant prostatecancer derived from quantitative analysis of the pten conditionalknockout mouse proteome. Eur Urol 2011; 60:1235-43.

10

publications

title

journalpaper/review

Cima I, Schiess R, Wild P, Kälin M, Schüffler P, Lange V, Picotti P, OssolaR, Templeton A, Schubert O, Fuchs T, Leippold T, Wyler S, Zehetner J,Jochum W, Buhmann J, Cerny T, Moch H, Gillessen Sommer S, AebersoldR, Krek W. Cancer genetics-guided discovery of serum biomarkersignatures for diagnosis and prognosis of prostate cancer. Proc Natl AcadSci USA 2011; 108:3342-7.

Ruhstaller T, Templeton A, Ribi K, Schuller J C, Borner M, Thierstein S,von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Popescu R.Intense therapy in patients with locally advanced esophageal cancerbeyond hope for surgical cure: a prospective, multicenter phase II trial ofthe Swiss Group for Clinical Cancer Research (SAKK 76/02). Onkologie2010; 33:222-8.

Schoch O, Templeton A, Spirig C, Thürlimann B. Interstitial pneumonitisafter treatment with bevacizumab and pegylated liposomal doxorubicin ina patient with metastatic breast cancer. Chemotherapy 2010; 56:69-70.

Omlin A, Kälin M, Templeton A, Gillessen Sommer S, Graf H J,Rothermundt C. Metastasiertes Prostatakarzinom –Behandlungsmöglichkeiten nach der Hormontherapie. Swiss MedicalForum 2010; 10:483-485.

Templeton A, Rothermundt C. Metastasiertes Nierenzellkarzinom -Moderne Behandlung bei fortgeschrittenem Stadium. Ars Medici 2010;15:598-602.

Ruhstaller T, Templeton A, Ribi K, Schuller J C, Borner M, Thierstein S,Von Moos R, Pederiva S, Lohri A, Lombriser N, von Briel C, Popescu R.Intense therapy in patients with locally advanced esophageal cancerbeyond hope for surgical cure: a prospective, multicenter phase II trial ofthe Swiss Group for Clinical Cancer. Onkologie 2010; 33:222-228.

11

publications

title

journalpaper/review

Joerger M, Templeton A, Engler H, Riesen W F, Thürlimann B. Procollagentype I N-propeptide is a predictor of skeletal morbidity in patients withmalignant osteolytic bone disease on bisphosphonates. CancerChemother Pharmacol 2010;.

Gillessen Sommer S, Templeton A, Marra G, Kuo Y F, Valtorta E,Shahinian V B. Risk of colorectal cancer in men on long-term androgendeprivation therapy for prostate cancer. J Natl Cancer Inst 2010;102:1760-70.

Templeton A, Thürlimann B, Joerger M. Ixabepilon bei lokalfortgeschrittenem oder metastasiertem Mammakarzinom: NeueBehandlungsoptionen nach Taxanen und Anthrazyklinen. SchweizerKrebsbulletin 2009;114-117.

Fokt R M, Templeton A, Gillessen Sommer S, Öhlschlegel C, Schmid H P.Prostatic metastasis of renal cell carcinoma successfully treated withsunitinib. Urol Int 2009; 83:122-4.

Fehr M, Templeton A, Cogliatti S B, Aebersold F, Egli F, Gillessen SommerS, Cathomas R. Primary manifestation of small lymphocytic lymphoma inthe prostate. Onkologie 2009; 32:586-8.

Templeton A, Marra G, Valtorta E, Heinimann K, Müller H, GillessenSommer S. Concordant colon tumors in monozygotic twins previouslytreated for prostate cancer. Familial cancer 2009; 8:167-71.

Templeton A, Brändle M, Cerny T, Gillessen Sommer S. Remission ofdiabetes while on sunitinib treatment for renal cell carcinoma. Annals ofoncology : official journal of the European Society for Medical Oncology /ESMO 2008; 19:824-5.

Templeton A, Hofer S, Töpfer M, Sommacal A, Fretz C, Cerny T, GillessenSommer S. Extraneural spread of glioblastoma--report of two cases.Onkologie 2008; 31:192-4.

12

publications

title

journalpaper/review

Templeton A, Schlegel M, Fleisch F, Rettenmund G, Schöbi B, Henz S,Eich G. Multilumen central venous catheters increase risk for catheter-related bloodstream infection: prospective surveillance study. Infection2008; 36:322-7.

Templeton A, Omlin A, Strasser F. An update on the pharmacologicalmanagement of the cancer anorexia-cachexia-syndrome. EuropeanJournal of Palliative Care 2007; 14:186-190.

Templeton A, Gillessen Sommer S. Sinnvoll?. Schweiz Med Forum 2007;7:469.

Templeton A, Engeler S, Boggian K. Varizellenpneumonie. Schweiz MedForum 2006; 6:.

Templeton A, Vonesch H J. Swollen leg with blisters. Praxis 2005;94:1569-74.

Templeton A, Vonesch H J. Intoxikation mit GBL ("liquid ecstasy").Schweiz Med Forum 2005; 5:115-116.

13

projects

title status

An open-label, multicohort, phase II study of MPDL3280A inadvanced solid tumors

ongoing- followup

14

projects

title status

A phase III, open-label, multicenter, randomized study toinvestigate the efficacy and safety of MPDL3280A (ANTI−PD-L1ANTIBODY) compared with chemotherapy in patients withlocally advanced or metastatic urothelial bladder cancer afterfailure with platinum-containing chem-otherapy. GO29294

ongoing- followup

SAKK 63/12 Prospective cohort study with collection of clinicaldata and serum of patients with prostate disease

ongoing- followup

Retrospective Analysis of mistletoe-induced fever in cancerpatients

completed

Metformin in castration resistant prostate cancer. A multicenterphase II trial

completed

15

projects

title status

Local antiperspirant for prevention of palmar-plantarerythrodysesthesia (PPE) in patients treated with pegylatedliposomal doxorubin: A randomized, multicenter, doubleblinded, phase III trial

completed

SAKK 08/08: Everolimus als Erstlinienbehandlung desKastrationsrefraktären Prostatakarzinoms – Einemultizentrische Phase II Studie

completed

What “extras” do breast cancer patients receiving adjuvanttherapy ask for?

completed

Multiepitop Imfpung von Grad III/IV Melanompatienten mitdendritischen Zellen: Bedeutung von Peptidaffinität und -dichtefür die optimale Generierung von tumorspezifischenzytotoxischen T-Lymphozyten

completed